dc.contributor.author
Klier, John
dc.contributor.author
Geis, Sabine
dc.contributor.author
Steuer, Jeanette
dc.contributor.author
Geh, Katharina
dc.contributor.author
Reese, Sven
dc.contributor.author
Fuchs, Sebastian
dc.contributor.author
Müller, Ralf S.
dc.contributor.author
Winter, Gerhard
dc.contributor.author
Gehlen, Heidrun
dc.date.accessioned
2018-06-08T10:48:25Z
dc.date.available
2017-11-08T09:32:18.026Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/21107
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24404
dc.description.abstract
Introduction: New therapeutic strategies to modulate the immune response of
human and equine allergic asthma are still under extensive investigation.
Immunomodulating agents stimulating T-regulatory cells offer new treatment
options beyond conventional symptomatic treatment or specific immunotherapy
for human and equine allergic airway diseases, with the goal of a homoeostatic
T-helper cell balance. The aim of this study was to evaluate the effects of a
nebulized gelatin nanoparticle-CpG formulation (CpG-GNP) with and without
specific allergens for the treatment of spontaneous allergic equine asthma as
a model for human asthma. Methods: Twenty equine asthma-affected horses were
treated either with CpG-GNP alone or CpG-GNP with allergens. Two specific
allergens were selected for each horse based on history and an in-vitro test.
Each horse received seven administrations of the respective nebulized
composition and was examined before treatment, immediately after and 6 weeks
after the treatment course. Results: Clinical parameters such as breathing
rate, indirect interpleural measurement, arterial blood gases, amount of
tracheal mucus and percentage of neutrophils and cytokines in tracheal washes
and serum samples were evaluated. Treatment with CpG-GNP alone as well as in
combinations with relevant allergens resulted in clinical improvement of nasal
discharge, breathing rate, amount of secretion and viscosity, neutrophil
percentage and partial oxygen pressure directly after and 6 weeks after
treatment. There were no significant differences between the two treatments in
clinical parameters or local cytokine profiles in the tracheal wash fluid
(IL-10, IFN-g, and IL-17). IL-4 concentrations decreased significantly in both
groups. Conclusion: Nonspecific CpG-GNP-based immunotherapy shows potential as
a treatment for equine and possibly also human allergic asthma.
de
dc.format.extent
16 Seiten
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
allergic asthma
dc.subject
extrinsic asthma
dc.subject
neutrophilic asthma
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::630 Landwirtschaft
dc.title
A comparison of nanoparticullate CpG immunotherapy with and without allergens
in spontaneously equine asthma-affected horses, an animal model
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Immunity, Inflammation and Disease 5 (2017)
dcterms.bibliographicCitation.doi
10.1002/iid3.198
dcterms.bibliographicCitation.url
http://doi.org/10.1002/iid3.198
refubium.affiliation
Veterinärmedizin
de
refubium.affiliation.other
Klinik für Pferde

refubium.funding
Deutsche Forschungsgemeinschaft (DFG)
refubium.mycore.fudocsId
FUDOCS_document_000000028452
refubium.note.author
Gefördert durch die DFG und den Open-Access-Publikationsfonds der Freien
Universität Berlin.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000009085
dcterms.accessRights.openaire
open access
dcterms.isPartOf.issn
2050-4527